Tuesday, November 25, 2014

N30 Pharma Finds $30M More

Boulder-based N30 Pharma has raised $30M more in a mezzanine funding round, the company disclosed last week, which came from Wellington Management, RA Capital Management, Jennison Associates, Rock Springs Capital Management, and Sabby Management, along Deerfield Management and others. The company--which is developing treatments for cystic fibrosis--said the funding goes towards advancing its lead compound, N91115. The company has now raised north of $115M in funding. More information »